TIDMAVO
RNS Number : 5312D
Advanced Oncotherapy PLC
20 February 2020
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the
publication of this announcement via a Regulatory Information
Service, this inside information is now considered to be in the
public domain.
20 February 2020
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
University Hospitals Birmingham NHS Foundation Trust and
Advanced Oncotherapy to collaborate over LIGHT system for proton
therapy cancer treatment
Advanced Oncotherapy to install a LIGHT system in collaboration
with UHB and engage with the development of further advanced
technical and clinical features
UHB and Advanced Oncotherapy will work together to increase
awareness of proton therapy for treatment of cancer
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment, is
pleased to announce that it has reached an agreement on the terms
for a collaboration with University Hospitals Birmingham NHS
Foundation Trust ("UHB"), the acute service provider delivering
general hospital services for Birmingham and specialist treatments
for the West Midlands and nationally, to install a LIGHT
system.
As part of the collaboration, Advanced Oncotherapy and UHB will
also work together on various research and development activities
associated with the use of LIGHT to increase the awareness of
proton therapy for the treatment of cancer. The collaboration
between Advanced Oncotherapy and UHB includes an agreement that an
appropriate revenue sharing arrangement will be implemented. It is
envisaged that the LIGHT system will be installed on the UHB
campus. The installation of LIGHT and the treatment of first
patients are subject to customary conditions and agreements being
in place, including obtaining all relevant approvals, consents and
authorisations, such as the certification of LIGHT.
UHB is one of the largest teaching hospital trusts in England
and one of the largest regional centres for non-surgical cancer
treatment serving a regional, national and international
population. The hospital group sees and treats more than 2.2
million patients every year across its sites, which include Queen
Elizabeth Hospital Birmingham, Birmingham Heartlands Hospital,
Solihull Hospital and Community Services, Good Hope Hospital in
Sutton Coldfield and Birmingham Chest Clinic. From a regional
aspect, UHB has established links with surrounding cancer units and
runs a number of smaller satellite units, allowing people to be
treated as close to home as possible.
Dr David Rosser, CEO of UHB, said:
"Our Trust is one of the largest regional centres for
non-surgical cancer treatments in the UK, with our
highly-specialised consultants working within a professional and
well-established team to provide the best possible care to
patients, their families and carers. This collaboration will
further strengthen our position as a Trust that embraces and
develops the next generation of technology to continually improve
outcomes and deliver healthcare that is fit for future
generations."
Nicolas Serandour, CEO of Advanced Oncotherapy, commented:
"We are pleased to announce this collaboration with University
Hospitals Birmingham NHS Foundation Trust, a leader in the
non-surgical cancer treatment field. The collaboration is aimed at
delivering best treatment modalities for patients and further
establishes our network of scientific partners, positioning
Advanced Oncotherapy at the forefront of clinical innovation. UHB's
choice of Advanced Oncotherapy not only strengthens our leading
position as technology disruptor in proton therapy, but also
demonstrates our strong momentum and the clear opportunity we have
to meet a significant unmet medical need: only 200 treatment rooms
today globally but a need of at least 10,000 treatment rooms if
only 20% of patients undergoing radiotherapy are treated with
proton therapy.
With three partnerships announced in the last two months - the
Cleveland Clinic, The London Clinic and the Mediterranean Hospital
of Limassol - this fourth agreement is another important step for
us as a Company and it is in line with our continuous commitment to
defeat cancer."
- ENDS -
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Tel: +44 (0) 20 3617 8728
Chairman
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad
& Broker)
Nick Athanas / Liz Kirchner / Tel: +44 (0) 20 3328 5656
Nicholas Chambers
FTI Consulting (Financial PR advancedoncotherapy@fticonsulting.com
& IR)
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
Notes for Editors
About UHB
UHB runs the Queen Elizabeth Hospital Birmingham, Birmingham
Chest Clinic, Heartlands Hospital, Good Hope Hospital, Solihull
Hospital and various community services across the region. It
employs more than 20,000 members of staff and treats over 2.8
million patients each year with more than 2,700 beds across its
sites.
The Trust has regional centres for trauma, burns, plastics,
neurosciences, dermatology and cancer. It also has centres of
excellence for vascular, bariatric and pathology services, as well
as the treatment of MRSA and other infectious diseases. It also has
expertise in HIV/AIDS, premature baby care, bone marrow transplants
and thoracic surgery.
The Queen Elizabeth Hospital Birmingham is a Major Trauma Centre
treating the most severely injured casualties from across the
region. The hospital's single site 100-bed critical care unit is
the largest in Europe.
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFFFLIFTIALII
(END) Dow Jones Newswires
February 20, 2020 02:00 ET (07:00 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2023 to Apr 2024